A Double-Blind, Placebo-Controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-Metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy
Phase of Trial: Phase III
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Male osteoporosis
- Focus Adverse reactions; Registrational
- Sponsors Amgen
- 14 Jun 2016 Status changed from active, no longer recruiting to completed.
- 08 Jun 2016 The trial was completed in Slovakia (end date: 2016-05-12).
- 03 Jun 2016 The trial was completed in Latvia (end date: 2016-05-12).